Capital Group Private Markets
Cancer drug developer Innovent Biologics files for HK IPO
Innovent Biologics, a Chinese drug developer company with a number of PE backers, has filed for an IPO in Hong Kong under recently introduced rules allowing listings by biotech companies with no revenue or profits.
Capital Group, GL buy stake in Chinese hospital operator
Capital Group Private Markets (CGPM) has joined GP Capital to invest in Jinxin Healthcare, the maternity care division of Chinese hospital operator Chengdu Jinxin Healthcare Investment Management Group (Jinxin Group).